Roche/Ipsen's anti-diabetic beats Byetta in first Phase III study
This article was originally published in Scrip
Executive Summary
Roche/Ipsen's anti-diabetic taspoglutide was both non-inferior and superior to Lilly/Amylin's Byetta (exenatide), as assessed by change in HbA1c levels, show the first top-line results from the drugs Phase III programme.